Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10190Neoplasms 7819Carcinoma, Non-Small-Cell Lung 5763Prostatic Neoplasms 5032Colorectal Neoplasms 4608Lung Neoplasms 3727Leukemia, Myeloid, Acute 3104Neoplasm Metastasis 3086Multiple Myeloma 3083Pancreatic Neoplasms 2846Melanoma 2654Ovarian Neoplasms 2578Lymphoma 2571Carcinoma, Hepatocellular 2483Stomach Neoplasms 2331Recurrence 2229Head and Neck Neoplasms 2106Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1906Glioblastoma 1799Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1695Lymphoma, Follicular 1655Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Large B-Cell, Diffuse 1598Carcinoma, Renal Cell 1579

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Primary Malignant Peripheral Nerve Sheath Tumors × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡